Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis

Science

Volumn 282, Issue 5387, 1998, Pages 290-293

  Bennett, Martin ^a   Macdonald, Kirsty ^a   Chan, Shiu Wan ^a   Luzio, J Paul ^a   Simari, Robert ^a   Weissberg, Peter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL SURFACE; GOLGI COMPLEX; HUMAN; HUMAN CELL; MEMBRANE TRANSPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; VASCULAR SMOOTH MUSCLE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIGENS, CD95; APOPTOSIS; BREFELDIN A; CARRIER PROTEINS; CELL MEMBRANE; CELLS, CULTURED; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; ETOPOSIDE; FAS LIGAND PROTEIN; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; GOLGI APPARATUS; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MUSCLE, SMOOTH, VASCULAR; MUTATION; PROTEIN SYNTHESIS INHIBITORS; RATS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032500793     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.282.5387.290     Document Type: Article

References (37)

1. M. Hollstein et al., Nucleic Acids Res. 22, 3551 (1994).
2. W. S. el Deiry et al., Cell 75, 817 (1993); M. Kastan et al., ibid. 71, 587 (1992); L. Buckbinder et al., Nature 377, 646 (1995); T. Miyashita et al., Oncogene 9, 1799 (1994); D. Israeli et al., EMBO J. 16, 4384 (1997); K. Polyak, Y. Xia, J. L. Zweier, K. W. Kinzler, B. Vogelstein, Nature 389, 300 (1997).
3. W. S. el Deiry et al., Cell 75, 817 (1993); M. Kastan et al., ibid. 71, 587 (1992); L. Buckbinder et al., Nature 377, 646 (1995); T. Miyashita et al., Oncogene 9, 1799 (1994); D. Israeli et al., EMBO J. 16, 4384 (1997); K. Polyak, Y. Xia, J. L. Zweier, K. W. Kinzler, B. Vogelstein, Nature 389, 300 (1997).
4. W. S. el Deiry et al., Cell 75, 817 (1993); M. Kastan et al., ibid. 71, 587 (1992); L. Buckbinder et al., Nature 377, 646 (1995); T. Miyashita et al., Oncogene 9, 1799 (1994); D. Israeli et al., EMBO J. 16, 4384 (1997); K. Polyak, Y. Xia, J. L. Zweier, K. W. Kinzler, B. Vogelstein, Nature 389, 300 (1997).
5. W. S. el Deiry et al., Cell 75, 817 (1993); M. Kastan et al., ibid. 71, 587 (1992); L. Buckbinder et al., Nature 377, 646 (1995); T. Miyashita et al., Oncogene 9, 1799 (1994); D. Israeli et al., EMBO J. 16, 4384 (1997); K. Polyak, Y. Xia, J. L. Zweier, K. W. Kinzler, B. Vogelstein, Nature 389, 300 (1997).
6. W. S. el Deiry et al., Cell 75, 817 (1993); M. Kastan et al., ibid. 71, 587 (1992); L. Buckbinder et al., Nature 377, 646 (1995); T. Miyashita et al., Oncogene 9, 1799 (1994); D. Israeli et al., EMBO J. 16, 4384 (1997); K. Polyak, Y. Xia, J. L. Zweier, K. W. Kinzler, B. Vogelstein, Nature 389, 300 (1997).
7. W. S. el Deiry et al., Cell 75, 817 (1993); M. Kastan et al., ibid. 71, 587 (1992); L. Buckbinder et al., Nature 377, 646 (1995); T. Miyashita et al., Oncogene 9, 1799 (1994); D. Israeli et al., EMBO J. 16, 4384 (1997); K. Polyak, Y. Xia, J. L. Zweier, K. W. Kinzler, B. Vogelstein, Nature 389, 300 (1997).
8. K. Ory, Y. Legros, C. Auguin, T. Soussi, EMBO J. 13, 3496 (1994).
9. E. Yonish-Rouach et al., Oncogene 11, 2197 (1995); L. Donatella Attardi, S. Lowe, J. Brugarolas, T. Jacks, EMBO J. 15, 3693 (1996); P. Sabbatini, J. Lin, A. Levine, E. White, Genes Dev. 9, 2184 (1995).
10. E. Yonish-Rouach et al., Oncogene 11, 2197 (1995); L. Donatella Attardi, S. Lowe, J. Brugarolas, T. Jacks, EMBO J. 15, 3693 (1996); P. Sabbatini, J. Lin, A. Levine, E. White, Genes Dev. 9, 2184 (1995).
11. E. Yonish-Rouach et al., Oncogene 11, 2197 (1995); L. Donatella Attardi, S. Lowe, J. Brugarolas, T. Jacks, EMBO J. 15, 3693 (1996); P. Sabbatini, J. Lin, A. Levine, E. White, Genes Dev. 9, 2184 (1995).
12. C. Caelles, A. Helmberg, M. Karin, Nature 370, 220 (1994); A. J. Wagner, J. M. Kokontis, N. Hay, Genes Dev. 8, 2817 (1994).
13. C. Caelles, A. Helmberg, M. Karin, Nature 370, 220 (1994); A. J. Wagner, J. M. Kokontis, N. Hay, Genes Dev. 8, 2817 (1994).
14. S. Rowan et al., EMBO J. 15, 827 (1996).
15. Y. Haupt, S. Rowan, E. Shaulian, K. Vousden, M. Oren, Genes Dev. 9, 2170 (1995); C. Ishioka et al., Oncogene 10, 1485 (1995).
16. Y. Haupt, S. Rowan, E. Shaulian, K. Vousden, M. Oren, Genes Dev. 9, 2170 (1995); C. Ishioka et al., Oncogene 10, 1485 (1995).
17. ™ was transfected into PA317 retroviral packaging cells. Recombinant retrovirus harvested at 48 hours was used to infect VSMCs, rat 1 fibroblasts, or MEFs in polybrene (8 μg/ml). Cells were selected in puromycin (2.5 μg/ml) and resistant cells were pooled.
18. T. Littlewood, D. Hancock, P. Danielian, M. Parker, G. Evan, Nucleic Acids Res. 23, 1686 (1995).
19. M. Bennett, T. Littlewood, S. Schwartz, P. Weissberg, Circ. Res. 81, 591 (1997).
20. S. Yonehara, A. Ishii, M. Yonehara, J. Exp. Med. 169, 1747 (1989); N. Itoh et al., Cell 66, 233 (1991).
21. S. Yonehara, A. Ishii, M. Yonehara, J. Exp. Med. 169, 1747 (1989); N. Itoh et al., Cell 66, 233 (1991).
22. 6) were incubated with CH-11 (20 μg/ml) for 30 min on ice followed by a secondary fluorescein isothiocyanate-conjugated anti-mouse IgG (Sigma). Total Fas expression was analyzed by permeabilizing cells in ethanol for 30 min before Fas staining. Higher expression of cytoplasmic compared with surface Fas was evident in rat and human fibroblasts, mesangial cells, and rat VSMCs, but not in THP-1 or HeLa cells.
23. R. Klausner, J. Donaldson, J. Lippincott-Schwartz, J. Cell Biol. 116, 1071 (1992); M. Ladinsky and K. Howell, Eur. J. Cell Biol. 59, 92 (1992).
24. R. Klausner, J. Donaldson, J. Lippincott-Schwartz, J. Cell Biol. 116, 1071 (1992); M. Ladinsky and K. Howell, Eur. J. Cell Biol. 59, 92 (1992).
25. DN-p53(302-370) encodes the oligomerization domain of p53 [E. Shaulian, A. Zauberman, D. Ginsberg, M. Oren, Mol. Cell. Biol. 12, 5581 (1992)].
26. R. Watanabe-Fukunaga, C. I. Brannan, N. G. Copeland, N. A. Jenkins, S. Nagata, Nature 356, 314 (1992); T. Takahashi et al., Cell 76, 969 (1994).
27. R. Watanabe-Fukunaga, C. I. Brannan, N. G. Copeland, N. A. Jenkins, S. Nagata, Nature 356, 314 (1992); T. Takahashi et al., Cell 76, 969 (1994).
28. 2-terminal death effector domain required for apoptosis.
29. C. A. Ray et al., Cell 69, 597 (1992); M. Tewari and V. Dixit, J. Biol. Chem. 270, 597 (1995); K. Smith, A. Strasser, D. Vaux, EMBO J. 15, 5167 (1996).
30. C. A. Ray et al., Cell 69, 597 (1992); M. Tewari and V. Dixit, J. Biol. Chem. 270, 597 (1995); K. Smith, A. Strasser, D. Vaux, EMBO J. 15, 5167 (1996).
31. C. A. Ray et al., Cell 69, 597 (1992); M. Tewari and V. Dixit, J. Biol. Chem. 270, 597 (1995); K. Smith, A. Strasser, D. Vaux, EMBO J. 15, 5167 (1996).
32. Time-lapse videomicroscopy examined the course of 100 randomly selected cells over 24 hours. Cumulative apoptotic deaths at 4-hour intervals were plotted against time. Mean deaths for each time point and experimental condition for a minimum of three independent experiments are given. Videomicroscopic measurements of apoptosis were confirmed against trypan blue exclusion (a measure of loss of viability).
33. ™ VSMC lysates were incubated with anti-Fas-protein G complexes (3 hours, 4°C), precipitated, separated by 10% SDS-polyacrylamide gel electrophoresis (PAGE) in nonreducing conditions, and blotted with mouse anti-human FADD IgC (1 μg/ml).
34. 2], and protease inhibitor cocktail (PIC, Sigma), resuspended in an equal volume of KEHM, and homogenized. The homogenate was centrifuged through a discontinuous sucrose gradient (1.6, 1.2, or 0.8 M sucrose in KEHM and PIC), and the Golgi-enriched fraction was collected from the 0.8/1.2 M sucrose interface, separated by 10% SDS-PAGE, blotted, and probed with mouse anti-Fas IgG (100 ng/ml) (#F22120, Transduction Labs). Fractions were compared against homogenate, and whole-cell lysate was isolated for protein immunoblots.
35. Retroviruses encoding pBabe Hygro FADD-DN or control vector (pBabe Hygro) [A. O. Hueber et al., Science 278, 1305 (1997)] were synthesized as in (10), cells were selected in hygromycin (200 μg/ml), and resistant cells were pooled.
36. A Nru-Dra III fragment from pcDNA3 crmA (16), cloned into the adenovirus shuttle plasmid pAdBglII, was cotransfected with Xba I-Cla I-digested sub360 genomic DNA [T. Ohno et al., Science 265, 781 (1994)] into 293 cells. Recombinant virus was isolated by plaque purification, propagated in 293 cells, and purified by caesium chloride centrifugation. Virus titers were determined by plaque assay. Target cell infection of 100% was obtained with a multiplicity of infection of 100 per cell.
37. ™, E. Nabel and G. Nabel for crmA adenovirus, D. Galloway for pLHPV-E6 type 16, A. Hueber for lpr and gld MEFs and pBabe DN-FADD, T. Suganuma for anti-galactosyl transferase, and F. Buss, G. Evan, and M. Oren for advice and comments. Supported by British Heart Foundation grants FS/ 97024, PG/95057, and PG/96040 (to M.B.) and CH/ 9400 (to P. W.), Medical Research Council grant G9310915 (to J.P.L), and NIH grant HL34073 and the Bruce and Ruth Rappaport Program in Vascular Biology (to R.S.).